Clinical Trials Browser

Phase 2 × INDUSTRY × Carcinoma, Small Cell × Clear all

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Carcinoma, Small Cell, Small Cell Lung Carcinoma, Prostatic Neoplasms, Castration-Resistant

NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Phase 2 Completed

139 enrolled 14 charts

EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

NCT00412880 2022-06-22

BI 2536 Second Line Monotherapy in SCLC

Phase 2 Completed

23 enrolled 10 charts

Carcinoma, Small Cell

NCT00298896 2018-07-26

Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer

Phase 2 Completed

55 enrolled 10 charts

Thoracic

Carcinoma, Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

NCT00046787 2011-10-20

Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer

Phase 2 Completed

47 enrolled

Thoracic

Carcinoma, Small Cell, Small Cell Lung Carcinoma

NCT00191750 2007-01-26

A Study of Pemetrexed in Small Cell Lung Cancer, Which Has Returned

Phase 2 Completed

80 enrolled

Carcinoma, Small Cell

Clinical Trials

Tamarack

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

BI 2536 Second Line Monotherapy in SCLC

Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer

Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer

A Study of Pemetrexed in Small Cell Lung Cancer, Which Has Returned